Bridging the gap — Establishing a dental-oncology service in a cancer centre

Abstract

Dental disease remains the most common non-communicable disease worldwide. It predisposes patients to significant morbidities following bone modifying agents or radiation therapy to the head and neck. Preventative dental regimes effectively reduce the risk of both medication-related osteonecrosis of the jaw (MRONJ) and osteoradionecrosis (ORN) in these patients. Co-ordination of routine dental care as a component of mainstream oncology treatment optimises long term outcomes for oncology patients. This case series offers insights into patient, institutional and social difficulties that challenge the dental-oncology interface. These obstacles and subsequent resolutions experienced whilst establishing a dental-oncology service in a cancer centre highlight the importance of effective multidisciplinary lead care for oncology patients. It reinforces the need for structured, supported dental pathways for these oncology patients.

Supplementary Information

The online version contains supplementary material available at 10.1007/s00520-024-08872-x.

Introduction

In dentistry, the term bridging refers to providing a connection or contact between two different subjects or matter [1]. The term also resonates in interdisciplinary care where bridges are created based on patient needs. Globally, dental disease has been the most common, non-communicable disease worldwide for over 3 decades [2, 3]. For oncologists, the dental-oncology interface is most evident in the conditions of medication-related osteonecrosis of the jaw (MRONJ) and osteoradionecrosis (ORN). These well-recognised conditions have devastating quality of survival implications for patients [4]. Improved cancer outcomes have led to increased number of at risk patients and consequently a requirement for greater integration of dentistry into cancer care. Traditionally, this care relied upon non-structured, individual patient constructed bridges. In this paper, we outline the benefits of establishing formal bridging pathways in cancer care.

The growing significance of the dental-oncology interface results from the widespread integration of bone modifying agents (BMAs) to combat skeletal-related events (SREs), bone metastases and hypercalcemia. SREs in cancer patients are associated with loss of mobility, reduced quality of life and healthcare expenditure [5–7]. BMAs are commonly prescribed to patients with prostate (85%), breast (70%), lung (40%), kidney (40%) cancer and multiple myeloma (95%) [8–10]. Their utilisation is integrated into guideline-based cancer care [9]. BMAs are also given to patients in the curative setting such as early breast cancer to reduce recurrence rates and improve survival [9]. MRONJ is the most concerning side effect of BMAs, a side effect compounded by the lack of dental integration into oncology practice. It follows a clinical path of exposed bone in the maxillofacial region, present for at least 8 weeks in a patient exposed to a BMA (anti-resorptive/anti-angiogenic) and excluding radiation therapy or metastatic deposit to the jaws [11]. The prevalence of MRONJ in cancer patients ranges from 0 to 12% [11][12, 13]. RANK-ligand inhibitors have been used as alternatives to bisphosphonates, and their prevalence of MRONJ ranges from 0.7 to 6.7% [14, 15]. Incorporation of bisphosphonates into the curative anti-cancer setting poses a long-term risk of MRONJ due to the long half-life of the agents with a MRONJ rate of 0.00 to 1.8% in clinical trials [16–18]. As outlined in case reports/series and cohort studies, MRONJ is also associated with targeted therapies (sunitinib, bevacizumab and imatinib), immunomodulators (infliximab, rituximab and everolimus), immunotherapies (ipilimumab, pembrolizumab and nivolumab), cytotoxic agents (5-fluorouracil, paclitaxel and azacytidine) and folate antagonist (methotrexate) [19–25].

Radiation therapy is used in almost 75% of patients with a head and neck squamous cell carcinoma as either primary or adjuvant therapy following primary resection or concurrent chemoradiotherapy for local advanced cancer and organ preservation [26, 27]. Radiation toxicity is implicated in hyposalivation, mucositis, dermatitis, dysphagia, dysgeusia and hoarseness. Chronic implications and late toxicity events of radiation therapy include osteoradionecrosis, a fibro-atrophic osseous change seen in 5 to 15% of patients who have been exposed to radiation therapy to the jaws. This usually develops following a dentoalveolar procedure such as a dental extraction [28]. The incidence of ORN increases with radiation doses above 60 Gy and the risk of development increases with time [29, 30]. Prophylactic extraction of unfavourable teeth in the field of radiation therapy is recommended prior to radiation exposure [31, 32]. Cancer care is time sensitive, placing added emphasis on timely dental management [32].

Dental disease is a mitigating factor for the development of MRONJ and ORN [13, 28]. Poorly controlled, severe periodontal disease and dentoalveolar surgery such as a tooth extraction elevate the risk of MRONJ and ORN [33]. Dental disease increases the prevalence of invasive dental procedures in patients following radiation therapy and BMAs [13, 34, 35]. The influence of preventative dental strategies has proven efficacious in the prevention of MRONJ and ORN [29, 36]. Elimination of over-reliance on patients to implement aspects of care such as long-term dental care and formal integration of preventative dental services prior to BMA and radiation therapy remains beneficial [37].

To date, the integration of dental care into oncology specialities is unstructured [38]. Improving the oral health status and reducing treatment needs in oncology patients will reduce morbidities of treatment-implicated consequences [37]. This article provides a cautionary message for clinicians regarding dental risks in these groups [16, 18, 39–42]. Integrating a dental-oncology service into cancer care may help optimise patient care as a component of the multidisciplinary care model [43]. In this paper, we use a case series derived from both at-risk patients for MRONJ and ORN development to highlight the needs and benefits of an integrative dental service.

Materials and methods

In Ireland, the community dental care service is operated by the Health Service Executive (HSE) Dental Service. Primarily, this is based in the primary care setting which is comprised of predominantly privately funded treatment with general dental practitioners. There is a limited availability of HSE operated, state-funded dental schemes. Such treatments are means tested based on weekly income, savings, investments and property, including spousal incomes. This community-based service offers a limited amount of dental treatment for head and neck oncology patients, and a limited availability of dental practitioners compounds its impact.

For head and neck cancer patients, dental treatment prior to radiation therapy is provided by the HSE to ensure patients are dentally suitable to commence radiation therapy to the head and/or neck. Following radiation therapy, means testing and limited state-funded dental care for oncology patients renders access to dental care challenging. Consequently, patients face many barriers to care including access issues and financial constraints while trying to navigate complex dental pathways. Currently, dental services for oncology patients operate as a reflex dental service rather than a pre-emptive one. Dental oncology guidance advocates 3 monthly recall reviews for oncology patients at risk of MRONJ and ORN [44, 45]. There is no structured pathway for cancer patients prior to BMAs [38].

In 2022, a pilot dental oncology program was established using grant funding (CiSA, College of Medicine and Health interdisciplinary Seeds Award). Oncology patients planned for BMA therapy were referred from various oncology services in Cork University Hospital (CUH). The CUH is a level 5 hospital with 800 beds; 25,000 in-patient admissions; 27,000-day cases and 58,000 emergency cases (A&E) every year and employs over 4000 staff. It is 1 of 8 adult National Cancer Control Programme (NCCP)-affiliated Cancer Centres and 1 of 54 acute hospitals in Ireland run by the HSE [46]. The CUH is collocated with the Cork University Dental School and Hospital (CUDSH), which is governed by the University College Cork and structured to facilitate pre-dental assessments for head and neck cancer patients under the HSE Cancer Service Level Agreement.

Regional head and neck cancer services based in the South Infirmary Victoria University Hospital (SIVUH) and CUH refer head and neck cancer patients for pre-radiation dental treatment in the CUDSH. We have included a radiation therapy case to highlight some challenges in this cohort. The case summaries are highlighted in Table 1.

Table 1.

Clinical details of six dental-oncology cases

Case number	Cancer diagnosis	Age	Stage	Planned BMA	Treatment
1	De novo metastatic, castrate sensitive prostate cancer	65 years	4	Zoledronic acid	First line: docetaxel, abiraterone and androgen deprivation therapy (ADT)
2	Hormone sensitive, HER2 negative breast cancer	55 years	2	Zoledronic acid	Surgery: mastectomy and sentinel lymph node biopsy Adjuvant: doxorubicin, cyclophosphamide and paclitaxel (AC-T), radiation therapy, hormone treatment
3	Hormone sensitive, HER2 negative breast cancer	43 years	2	Zoledronic acid	Neoadjuvant: AC-T (in Ukraine) Surgery: mastectomy and axillary lymph node clearance (in Ukraine) Adjuvant: tamoxifen, zoladex (2 years previously)
4	De novo metastatic, castrate sensitive prostate cancer	61 years	4	Zoledronic acid	First line: docetaxel, abiraterone, androgen deprivation therapy (ADT)
5	Metastatic castrate resistant prostate cancer	81 years	4	Denosumab	Not currently on treatment. Multiple prior lines including ADT, chemotherapy, abiraterone and radium-223
6	Head and neck cancer	59 years	4a	Radiation therapy	Primary surgery, reconstruction and adjuvant radiation therapy

Case-based scenarios — patient cohort

Case 1

A 65-year-old male with de novo metastatic prostate cancer and bone-dominant disease was referred for a dental assessment. He had a longstanding history of dental neglect, uncontrolled periodontal disease (stage 3, grade B, British Society of Periodontology classification system [47]) and periapical infections. He had a 20-pack year smoking history, had not seen a dentist in over 7 years, nor was he registered with one. The treatment plan included 9 dental extractions, intensive periodontal therapy, provision of partial dentures, integration into the community care dental services and co-ordination with oncology throughout his dental care visits in tandem with his oncology chemotherapy treatment. He had a high dental treatment need and transitioning the patient into a partial dentition with dentures was challenging. See Fig. 1 which highlights the challenges experienced in case 1.

Fig. 1.

Summary of pre-existing MRONJ exacerbation factors (smoking and severe periodontal disease), and a high dental treatment need

Case 2

A 55-year-old post-menopausal female with early stage breast cancer presented for a dental assessment. She was scheduled for adjuvant chemotherapy, hormone treatment and BMA therapy. She complained of recurrent dental pain and swelling associated with a lower right wisdom tooth. The patient lived alone and could not drive. Risk factors for dental complications included chemotherapy treatment, smoking (20 pack years) and recurrent wisdom tooth infections. Extraction of her lower right wisdom tooth would place the patient at high risk of lower lip and chin paraesthesia due to the intimate nature of her wisdom tooth and inferior alveolar nerve. As a consequence of this relationship, staged oral surgery procedures were required to initially surgically section the crown off the impacted wisdom tooth, actively monitor for 3 months and then surgically remove the roots after they dissociated themselves from the inferior alveolar nerve. This staged, surgical approach was necessary to alleviate her pain, reduce the risk of permanent numbness to the lower lip and chin and eliminate the source of infection prior to BMA therapy. As a result of post-operative infection, her treatment plan also included 3 months of intense aftercare and wound debridement following decoronation of the wisdom tooth. Treatment was supported by meticulous wound-care in the oral surgery department throughout chemotherapy, antibiotic therapy and at-home oral hygiene regimes. We reinforced the importance of smoking cessation and effective multidisciplinary communication throughout chemotherapy, alongside the co-ordination of BMA therapy, following surgical removal of the wisdom tooth roots. She was integrated into the community-based dental service with 3 monthly dental reviews following administration of her BMA.

Case 3

A 43-year-old pre-menopausal Ukrainian refugee receiving adjuvant hormone treatment for early stage breast cancer was referred prior to BMA treatment. Her oncology treatment was initially commenced in the Ukraine; however, conflict there led to her seeking refugee status in Ireland. The patient was a poor dental attender in Ukraine for the previous 7 years. She did not speak English, did not possess a mobile phone and did not have a means of transport to the dental hospital. The patient failed to attend 3 dental hospital appointments over an 8-week period prior to the initial dental consultation. This impacted on the timely commencement of her BMA treatment. The reason for poor attendance was attributed to her movement between refugee centres, lack of direct means of contact and difficulties in accessing the patient directly in refugee homes. When she attended, treatment was also delayed due to access barriers to translation services. This case highlighted the lack of service familiarity, consequences of displacement, cost implications and co-ordination challenges between patient and translator. The translator service was also redundant on multiple occasions as the patient failed to attend appointments while the translator was present. The challenges involved both social and demographic prerequisites to language barriers, social instability, communication and poor access to routine health care services and have persisted during integration with a community dental service.

Case 4

A 61-year-old male with de novo metastatic prostate cancer requiring BMA treatment was referred for a dental assessment. He complained of long-standing dental pain and mobility of some posterior teeth. He had a 20-year-pack history of smoking both cigarettes and cannabis and consumed 45 units of alcohol per week. The patient had not attended a dentist in the previous 5 years and was not registered with a general dental practitioner. Routine examination revealed uncontrolled periodontal disease (stage 3, grade B, British Society of Periodontology classification system [47]), 3 unrestorable molar teeth and two hyperplastic, heterogeneous plaques along the palatoglossal folds, concurrent with smoking-related mucosal changes. The patient received a course of periodontal debridement, extraction of the 3 unrestorable teeth and incisional biopsies of the heterogeneous soft tissue plaques. Both incisional biopsies revealed pre-cancerous, mucosal changes (moderate dysplasia) following histopathological examination. Routine dental examinations not only assess dental disease but also oral cancer screening which is a vital component of all dental examinations. The resolution for this patient incorporated an educational strategy to combat the social risk factors of oral cancer; smoking and alcohol. Invasive dental procedures such as extractions and biopsies were completed over multiple sessions to acclimatise the patient to dental work under local anaesthetic. Review regimes remained challenging due to the patients’ poor attendance and long-standing history of dental neglect and avoidance. We liaised with oral medicine colleagues who now actively monitor the moderate dysplasia on a 3–6 monthly review in a designated dysplasia clinic. Long-term integration into community dental services for long-term dental care remains challenging due to the patients’ poor compliance with oral health regimes. See Fig. 2 for a summary of the patients’ onco-dental issues.

Fig. 2.

A summary of the social and dental factors is depicted in Case 5. Routine dental examinations prior to BMA treatment are important to identify dental disease alongside mucosal examination and oral cancer screening

Case 5

An 81-year-old male with metastatic castrate resistant prostate cancer requiring both hormone and BMA treatment presented for dental assessment. He was previously assessed by the dental service 12 months prior, where he did not achieve dental fitness. The patient had severe, uncontrolled periodontitis (stage 3, Grade C, British Society of Periodontology [47]). He required multiple dental extractions due to their poor prognosis, extensive mobility and associated periodontal disease. The patient was also a native French Canadian speaker with poor English and required a translator. He returned for 2 further consultations to rediscuss his dental status and the proposed treatment plan including long-term periodontal root debridement therapy and multiple dental extractions. The patient had an inherent reluctance to proceed with the proposed plan due to an apprehension about his functional and chewing capacity thereafter. He refused all forms of invasive dental treatment such as extractions. We proceeded with the periodontal root debridement therapy; however, the patient subsequently decided to refrain from all dental treatments after the initial phase of periodontal therapy. There was a 14-month delay in BMA treatment in this case due to the patients’ reluctance to proceed with invasive dental treatment. Long-term dental care was not accepted in this case, and the patient proceeded with BMA treatment. He remains a high risk for MRONJ.

Case 6

A 59-year-old male patient with head and neck cancer presented following primary resection of his intraoral tumour, neck dissection and reconstruction with a fibula free flap, was planned for adjuvant radiation therapy. The patient was 2 weeks post-surgery and had a high level of post-operative care demands. He was on an intense analgesic regime and had airway challenges due to the recent decannulation of his tracheostomy. The surgical sites included the tracheostomy site, the neck dissection, the lower lip split/segmental mandibulectomy, free flap site in the left mandible and floor of mouth, donor site from the fibular free flap and abdomen skin graft donor site. His mouth opening was limited at 25 mm, and he currently was taking a direct oral anti-coagulant (apixaban) for atrial fibrillation. The patient was transferred with nursing staff to the CUDSH for a dental assessment prior to radiation therapy. The patient had an impacted, symptomatic, lower left wisdom tooth (Class 2, level B[48]). There was evidence of long-standing pericoronitis associated with the lower left wisdom tooth. Operative difficulties included limited access due to trismus, extensive cancer-related intra and extraoral healing surgical sites and anti-coagulant considerations for the surgical removal of the lower wisdom tooth. The patient also had a low mood and poor engagement with medical advice, stemming from his recent, intensive surgery and difficult initial post-operative recovery phase. He required the surgical removal of his impacted wisdom tooth by a specialist oral surgeon. Careful holistic planning at cancer diagnosis should integrate necessary surgical dental procedures with the concurrent cancer-directed surgery. The patient was seen regularly during his radiation therapy for supportive, preventative dental measures and introduced back to his private dental practitioner following the radiation therapy.

Table 2 below summarises the dental and oncology challenges that arose in these 6 clinical cases. The oncology cohorts have a high burden of care and challenges following cancer treatment. The resolutions of their onco-dental challenges are also highlighted in Table 2 which may serve as a template for future integration of dental services into oncology care.

Table 2.

Summary of dental issues, oncology challenges and resolution for each clinical-based scenario

Case number	Dental issue	Oncology challenge	Resolution
Case 1	Poor pre-existing dental health Extraction of 9 teeth — functional adjustment to dental prosthesis	Burden of treatment, co-ordination of invasive dental care Rural living and transport barriers to frequent health care	Access to dental care Multidisciplinary co-ordination Transition to partial dentition
Case 2	Dental infection on presentation High risk of morbidity following surgical extraction/neural disturbance High risk of post-operative infection	Management of chemotherapy and post-operative infection interface Access to care — transport barriers	Multidisciplinary co-ordination Patient education and support throughout oral surgery recovery
Case 3	Chronic periodontitis Refugee Service and language barrier Infrequent dental attender (7 years ago)	Social challenges Inconsistencies in oncology treatment between countries Transport and technological barriers	Provision of translation and communication support Multidisciplinary support and access to dental service Co-ordination of transport
Case 4	Dental phobia Dental neglect and unreliable attender Significant cigarette smoker Uncontrolled dental disease Pre-malignant oral mucosal changes (moderate dysplasia)	Intense treatment regime Social and educational barriers	Smoking cessation Pre-malignant mucosal monitoring Regular mucosal review regime in tertiary setting
Case 5	Uncontrolled severe periodontitis Poor dental care compliance Resilience to engage with necessary pre-BMA dental intervention	Delayed commencement of BMA therapy High risk of MRONJ	Time for patient education, support and communication Engagement with periodontal maintenance programme after 12 months
Case 6	Symptomatic, impacted lower wisdom teeth	Delayed commencement of radiation therapy due to surgical removal and awaiting mucosal coverage	Proposition for invasive dental extractions at the time of primary resection

Discussion

In this report, the multifaceted challenges to providing a dental oncology service are outlined. See Fig. 3 which provides an overview of the multifaceted nature of onco-dental challenges. The challenges predominantly include social, demographic, medical, cultural and financial restraints. These cases demonstrate inherent social and dental challenges such as dental phobia and dental neglect which are endemic in a cohort with pre-existing dental disease. Disruption of oncology treatment plans are evident alongside financial, health literacy, language and transport restraints. Oral healthcare is isolated from mainstream oncology. As a result, patients are responsible for accessing dental services and ensuring their dental needs are met. Reducing the burden of dental care and self-reliance on patients encourages the development of dental incorporation and services into oncology [49]. Barriers to dental care provision such as timing or insufficient time prior to commencing BMA or radiation therapy, lack of patient education regarding oral complications of BMAs and radiation therapy, co-ordination of healthcare specialities and lack of dentist confidence to treat this cohort are all modifiable factors for a service to address [50, 51]. Designated dental services have the potential to eliminate barriers to care.

Fig. 3.

Illustration highlighting the range of challenges that face patients and dental-oncology teams for patients receiving BMAs. The diagram below depicts a flow chart for patients at risk of MRONJ and the barriers to care

Managing care pathways pose challenges; however, identifying vulnerable patients requires vigilance from all healthcare professionals [52]. Since 2009, dental oncology integration has been shown to reduce MRONJ rates [53]. When referrer barriers are eliminated, it can lead to a 12-fold decrease in MRONJ in patients following their pre-medication dental examination [15]. Preventative dental strategies have a positive impact and help reduce the rate of MRONJ development [53–55]. Recognition of MRONJ in the early stages has a better prognosis, and lesser invasive therapies are required [56, 57]. The early incorporation of dental services for the head and neck oncology cohort has also proven beneficial. The inclusion of dental professionals into multidisciplinary team (MDT) meetings for head and neck oncology patients has allowed prompt assessment of the oral health status, and treatment of active dental disease prior to radiation exposure [58]. Additional benefits include reduction of potential radiation treatment timeframe delays, reduction in the burden of post radiation dental treatment needs, improved oral health-related quality of life and increased patient and provider education [58, 59]. Dental-oncology integration in an MDT setting with BMA therapy however remains sparsely documented in the literature and suggests suboptimal levels of integration. A recent review by Lim et al. in 2024 assessed the prevalence of dental assessments in 15,357 metastatic breast and prostate cancer patients, where 11.1% underwent dental check-ups prior to BMA treatment [60]. This contrasts with several guideline-based documents advocating such integration. The Royal College of Physicians 2019 document offers a collaborative approach to reduce the risk of MRONJ and integrate dental preventative service into oncology regimes [61]. In the USA, MASCC/ISOO/ASCO Clinical Practice Guideline on Medication-Related Osteonecrosis of the Jaw published in 2019 has also provided clinical guidance for oncologists on best practice to prevent MRONJ in oncology [13]. Introduction of a standardised pathway for oncology patients and considerations of real-time challenges is an important step towards the optimal standard of care for this cohort [62]. Both American and European collaborations are published in the literature to encourage pre-emptive integration of efficient dental services in oncology [11, 13, 36, 63–65]. Clinical guidance influences service provision and integration in local oncology communities to ensure cohesive dental care in the oncology setting. The National Cancer Strategy in 2017–2026, published by the National Cancer Control Programme (NCCP) in Ireland, has included a note on the importance of regular oral cancer screenings with a dentist and the inclusion of pre-radiation dental assessments prior to head and neck radiation therapy. Recommendations regarding access to care, dental care as a component of BMA therapy and post-treatment dental regimes were not included [38].

A cost analysis of state-funded dental care for head and neck oncology patients in Sweden revealed dental care consumptions increased significantly with cancer diagnosis, with statistically significant increase in dental costs and number of procedures [66]. These figures declined 2 years following cancer diagnosis but remained persistently higher compared to non-irradiated paired controls [66]. Patients were covered under a state-funded dental insurance scheme which compensated them for extensive dental rehabilitation. A special care allowance for radiation-related disease such as hyposalivation included an additional allowance to ensure maintenance of oral care in vulnerable cohorts [66]. A cost analysis for irradiated patient in this study was 900 euro compared to 210 euro in non-irradiated patients [66]. Cost effectiveness strategies and analyses of claims data reported the impact a dental service can have on an oropharyngeal service by reducing the cost of treatment and length of days required for treatment compared to reduced dental support [32, 66]. Acute oral complications were more expensive (1672 USD) when treated without dental integration. Average treatment times were 74 days shorter with immediate involvement of a dentist in an oropharyngeal cancer service, and dental decay was reduced [67]. In the present study oncology patients will benefit from direct involvement with dental services designated for pre-BMA and pre-radiation treatment alongside integration into community dentistry for long-term care [68].

A growing additional facet of dental oncology is the care of the displaced cancer patient. Based on Data from the United Nations High Commissioner for Refugees (UNHCR), 110 million people had been forcibly displaced, and 36.4 million people were refugees in mid-2023 [69]. Since Russia’s military aggression on Ukraine in February 2022, Europe has received the largest influx of people fleeing war since World War II. Oncology services must begin to accept the increased prevalence of refugees and the necessity to facilitate healthcare for this cohort of patients [70]. Ireland remains prominent in the promotion of inclusive policies to facilitate “intercultural healthcare” specifically targeting migrants’ health [70–72]. Irish society has become increasingly diverse related to immigrants, people seeking asylum and the impact of war in neighbouring continents [73]. Translation, transport and communication challenge healthcare provision to refugees. In Ireland, major oncology centres have access to two dental hospitals in Dublin and Cork. Relationships and co-located dental-oncology services require the uptake of facilities, finance, structural and organisational initiatives to foster improvements in healthcare [49]. However, global studies have highlighted substandard access particularly in mental health and dental care services within migrant populations [74]. Oral health tends to be poorer in refugee populations. A study of 12-year-old migrants in Austria demonstrated 42% higher rate of decay and more affected by gingivitis in migrant children compared to children with no migrant background [74, 75]. Language barriers significantly impact the quality of care in refugees. Cross-cultural consultations can be hindered by lack of healthcare staff awareness of resources, societal racism, ethnocentrism, engagement of senior HSE and governmental offices and the financial concerns regarding access to professional interpreting services were shown to hinder service provision [72, 76]. Barriers to care have deleterious consequences for cancer outcomes in migrant populations [77–79]. Migrants’ vulnerabilities include poorer psychological and health-related quality of life outcomes [80]. Dental workforce planning, professional interpreters, funding, research and awareness can facilitate communication and integration of healthcare for a multicultural nation.

De-escalation of BMAs in patients with both metastatic and early disease in breast cancer is advocated due to adverse symptomatic skeletal events, quality of life and healthcare expenditure [9, 81–84]. The literature has demonstrated the equivalent benefit of de-escalated regimens in patients with bone metastases, irrespective of completing 1 year of standard BMA treatment [85, 85]. The long-term implications of dental disease, dental interventions and risk of MRONJ persist for at least the half-life of the BMA therapy (11.2 years for intravenous zoledronic acid). This is also reiterated for the patients at risk of ORN, which increases in risk over time [30]. Long-term integration of dental services, patient awareness and proactivity to maintain healthy oral health statuses remain challenging [86, 87].

The challenges highlighted in this case series will increase in coming decades. The Irish Longitudinal Study on Ageing (TILDA) have highlighted a national population shift using a microsimulation which projected a growing cohort of elderly patients nationally with increased health and related outcomes in the years 2018–2040 [88]. This increasing aging population will place significant demands on the long-term effects of chronic conditions and legacy of oncological treatment, such as MRONJ and ORN. The dental demands of the elderly including aging dentition and oral physiological changes such as hyposalivation, medication-induced mucosal changes, reduced oral hygiene abilities and dexterity, mental impairment and reduced calorific nutrition will compound vulnerabilities to MRONJ and ORN in the growing cohort of cancer survivors [89]. Preventative strategies play a pivotal role in these populations. This population will see an increase in healthcare utilisation, functional limitations and burden of chronic illness impacting our service provision in the future [88].

Conclusion

The prevention of MRONJ and ORN is documented worldwide from an array of both medical and dental organisations. Dental care is a subsidiary of oncology care for patients with both early and late-stage cancer on BMA regimes and receiving head and neck radiotherapy. Dental integration into multidisciplinary cancer care can have significant quality-of-life implications for patients treated in both the curative and palliative settings. Historically such integration has been patient dependent compounding the impact of pre-existing dental disease — the world’s most prevalent non-communicable illness. The changes of dental oncology integration have grown with age as Ireland’s population becomes more ethnically diverse. Addressing these challenges will require more formulated cohesion between cancer centres and dental practitioners, analogous to those seen from integration of psycho-oncology services. In response to this, a pilot dental oncology service has been launched in 2022 in our centre integrating dental oncology into routine cancer care [68]. This paper raises some real-world challenges that can occur for both service and patient experience. Valuable lessons can be taken from this experience.

Supplementary Information

Below is the link to the electronic supplementary material.

Author contributions

All authors contributed to the production of the manuscript. Harriet Byrne and Claire Curtin collected and analysed data. Harriet Byrne complied the figures and tables.

Funding

This project was funded in part by the College of Medicine and Health Interdisciplinary Seeds Award (CiSA), University College Cork.

Data Availability

Data is available as supplementary information.

Declarations

Ethics approval

The ethical approval application was submitted to the Clinical Research Ethics Committee (CREC), University College Cork (UCC under the title “Oral Health Status and Dental Treatment Needs of Oncology Patients Receiving Bone Modifying Agents”. The research team included Dr Harriet Byrne (oral surgery speciality registrar), Professor Seamus O Reilly (consultant in medical oncology) and Professor Richeal Ní Riordáin (consultant in oral medicine). The stakeholders included University College Cork (UCC) and Health Service Executive (HSE), and the research project was conducted in the Oral Surgery Department, Cork University Dental School and Hospital, Wilton, Co Cork. The study was conducted in accordance with the requirements of the WMA Declaration of Helsinki (2008). Written informed consent will be obtained from all the participants.

Consent to participate and publish

The authors affirm that human research participants provided informed consent for publication of the data and qualitative findings within this paper.

Conflict of interest

Authors have no conflict of interest to declare.